Crescent Biopharma Inc Dossier - Source-backed chat

Crescent Biopharma Inc

CBIONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.89

Intrinsic Value $26.99median of 2 methodsbased on filings through 30 Jun 2026

Market Price $14.26Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 89% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+89%)

Data confidence Sign in to view data confidence

Market Cap $529.7M

Enterprise Value $358.1M

Shares Outstanding 37.1M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Crescent Biopharma is a highly promising clinical-stage oncology company advancing a robust pipeline of next-generation therapeutics, led by its PD-1 x VEGF bispecific antibody (CR-001) and novel antibody-drug conjugates (CR-002 and CR-003). By leveraging cooperative pharmacology validated by third-party clinical successes (such as ivonescimab), Crescent is positioned to establish CR-001 as a best-in-class immuno-oncology backbone. Backed by a strong strategic partnership with Sichuan Kelun-Biotech and a solid cash runway extending into 2028, the company offers a compelling risk-reward profile ahead of multiple key clinical readouts starting in early 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$27.00

Mean target$31.00

High · most bullish analyst$35.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Clinical trials encounter safety concerns, such as severe adverse events related to VEGF or PD-1 inhibition, or show insufficient efficacy compared to emerging competitors. Regulatory delays postpone the IND clearance for CR-002 or the initiation of combination trials. High R&D cash burn accelerates, forcing the company to raise capital under unfavorable market conditions, leading to substantial shareholder dilution.

Base CaseCentral scenario

Crescent successfully executes its ongoing global Phase 1/2 ASCEND trial for CR-001, delivering positive proof-of-concept data in Q1 2027. The company initiates clinical trials for CR-002 and combination regimens in H2 2026 as planned. Strategic collaboration with Kelun-Biotech continues to yield valuable clinical data, validating the synergistic potential of combining CR-001 with topoisomerase inhibitor ADCs. Cash runway remains sufficient to reach major clinical milestones without excessive near-term dilution.

Bull CaseUpside scenario

Strong institutional backing and insider buying, highlighted by Fairmount Funds Management's $12.3 million open-market purchase in July 2026, combined with a robust clinical-stage oncology pipeline targeting multiple pathways (such as lead candidate CPB-201 blocking PD-L1 and neutralizing TGF-β) and a consensus 'Strong Buy' or 'Moderate Buy' rating from Wall Street analysts with price targets implying over 90% upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Lead asset CR-001 is designed with cooperative pharmacology similar to ivonescimab, which has demonstrated superior clinical efficacy over pembrolizumab.
Strong strategic partnership with Sichuan Kelun-Biotech provides global development rights for promising ADC assets (CR-003) and co-development synergies.
Robust balance sheet with $189.2 million in cash as of March 31, 2026, providing a runway into 2028 that fully funds multiple clinical readouts.
Highly experienced management team with a proven track record in oncology drug development and capital allocation.

Key Investment Risks

Clinical-stage binary risk: The company's valuation is heavily dependent on upcoming Phase 1/2 data readouts in 2027.
Intense competition in the PD-1/VEGF bispecific and ADC landscapes from established pharmaceutical giants and other biotech players.
High operational cash burn typical of clinical-stage biotechs, requiring future dilutive capital raises if clinical timelines extend.

Thesis Invalidation Triggers

Failure of CR-001 to show meaningful antitumor activity or acceptable safety in the ASCEND trial Q1 2027 readout.
Severe safety signals or toxicities observed in the CR-002 or CR-003 clinical trials that halt development.
Inability to initiate planned ADC combination trials in the second half of 2026 due to regulatory or manufacturing delays.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.